CT-388

CT-388 is a dual GLP-1 receptor agonist, and GIP receptor agonist and modulator, with little to no beta-arrestin coupling at either receptor. It is made to be given once a week by injection. The drug is made by the pharmaceutical companies Roche (Swiss) and Genentech (American). 



Research

In a 24-week trial, participants averaged 18.8% placebo adjusted weight loss.

References

Category:Chemicals